Research Foundation and Clinical Development
Original Clinical Development and MHRA Approval
Sildenafil was originally developed by Pfizer in the 1990s as a potential treatment for cardiovascular conditions. During clinical trials, researchers observed its significant effects on erectile function, leading to extensive studies specifically for erectile dysfunction treatment. The landmark clinical trials involved thousands of men across different age groups and underlying health conditions, establishing the foundation for regulatory approval in 1998.
Key Clinical Trial Results
Pivotal studies demonstrated that sildenafil significantly improved erectile function compared to placebo across multiple measures. In controlled trials, approximately 70-80% of men reported improved erections with sildenafil treatment, compared to 25% with placebo. These studies included men with various underlying causes of erectile dysfunction, including diabetes, cardiovascular disease, and psychological factors. The research showed consistent benefits across different age groups, though response rates were generally higher in younger men.
Long-term Safety and Efficacy Studies
Extended follow-up studies have tracked patients using sildenafil for several years, providing valuable data on long-term safety and sustained effectiveness. These studies indicate that sildenafil maintains its efficacy over time, with many patients continuing to experience benefits after years of use. Long-term safety data shows that serious adverse events remain rare when sildenafil is used appropriately under medical supervision.
Comparative Research: Branded vs Generic
Bioequivalence studies demonstrate that generic sildenafil formulations provide equivalent therapeutic effects to branded Viagra. These studies measure how the medication is absorbed and metabolised in the body, confirming that generic versions deliver the same active ingredient in therapeutically equivalent amounts. This research supports patient choice between branded and generic options based on individual preferences and cost considerations.
Real-World Evidence and Post-Market Studies
Beyond controlled clinical trials, real-world evidence from millions of prescriptions worldwide provides additional insights into sildenafil's effectiveness in routine clinical practice. These studies include diverse patient populations and various co-existing health conditions, offering a broader perspective on treatment outcomes. Post-market surveillance continues to monitor safety profiles and identify any rare adverse effects not detected in initial trials.
Current Research and Ongoing Studies
Research into sildenafil continues, with ongoing studies investigating optimal dosing strategies, combination therapies, and its use in specific patient populations. Current research also explores the psychological benefits of successful ED treatment and its impact on overall quality of life and relationships. EverydayMeds provides access to both branded Viagra and generic sildenafil, allowing patients to choose their preferred option following clinical assessment by UK-licensed prescribers.
